Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.17.

EBIT: As of FY2026 Q2, the actual value is USD -36.53 M.

Cash Position

Century Therapeutics, Inc. reported cash, cash equivalents, and investments of $197.2 million as of June 30, 2026, an increase from $117.1 million as of December 31, 2025.

Research and Development (R&D) Expenses

R&D expenses for the quarter ended June 30, 2026, were $19.6 million, a decrease from $26.9 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $36.7 million, compared to $53.439 million for the six months ended June 30, 2025. This reduction was primarily due to a decrease in personnel and facility costs following portfolio prioritization.

General and Administrative (G&A) Expenses

G&A expenses were $5.8 million for the quarter ended June 30, 2026, down from $7.8 million for the same period in 2025. For the six months ended June 30, 2026, G&A expenses totaled $12.366 million, compared to $16.212 million for the six months ended June 30, 2025.

Net Income (Loss)

Net loss for the quarter ended June 30, 2026, was - $34.6 million, compared to a net loss of - $32.5 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $56.195 million, contrasting with a net income of $44.019 million for the six months ended June 30, 2025.

Other Financial Metrics

• Loss on lease component termination was $11.145 million for both the three and six months ended June 30, 2026.
• Total operating expenses were $36.527 million for the quarter ended June 30, 2026, and $60.211 million for the six months ended June 30, 2026.
• Income (loss) from operations was - $36.527 million for the quarter ended June 30, 2026, and - $60.221 million for the six months ended June 30, 2026.
• Interest income was $1.982 million for the quarter ended June 30, 2026, and $4.001 million for the six months ended June 30, 2026.
• Total assets were $287.006 million as of June 30, 2026, up from $223.704 million as of December 31, 2025.
• Total liabilities were $54.661 million as of June 30, 2026, down from $64.768 million as of December 31, 2025.
• Total stockholders’ equity was $232.345 million as of June 30, 2026, up from $158.936 million as of December 31, 2025.

Operational Highlights

Century Therapeutics, Inc. completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy. Preclinical data for CNTY-813 demonstrated durable glucose control in vivo, immune evasion, and successful manufacturing at clinical scale. The company also established its Phase 1 clinical manufacturing bioreactor process for CNTY-813.

Outlook and Guidance

Century Therapeutics, Inc. expects to submit an Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027. CNTY-308 is projected to enter the clinic in 2026. The current cash, cash equivalents, and investments are estimated to support operations into the first quarter of 2029.